What Is Glipizide Used For?

The Primary Use: Controlling Blood Sugar in Type 2 Diabetes

Glipizide is indicated solely for glycemic control in adults diagnosed with type 2 diabetes mellitus (T2DM), used either as monotherapy or in combination with other oral antidiabetic agents or insulin. The FDA label specifies it as an adjunct to diet and exercise, not a replacement for lifestyle modification. Glipizide works when functioning beta cells remain in the pancreas, which is why it has no role in type 1 diabetes. [1]

Type 2 diabetes affects approximately 38.4 million Americans, or 11.6% of the U.S. population, according to the CDC's 2023 National Diabetes Statistics Report. [2] Within that population, sulfonylureas like glipizide remain widely prescribed because they are inexpensive, orally administered, and reliably lower fasting plasma glucose within days of initiation.

The American Diabetes Association (ADA) 2024 Standards of Care in Diabetes lists sulfonylureas as a second-line add-on after metformin when cost is a primary concern or when cardiovascular and renal comorbidities are absent. [3] Glipizide is the sulfonylurea of choice in many clinical settings because it has a shorter half-life (2 to 4 hours) than glibenclamide (glyburide), which reduces the duration and severity of hypoglycemic episodes. [4]

A 2021 review in the journal Diabetes Care noted that second-generation sulfonylureas, including glipizide and glimepiride, produce mean HbA1c reductions of 1.0 to 2.0 percentage points from baseline, comparable to metformin's effect in drug-naive patients. [5]

How Glipizide Works: The Mechanism of Action

Glipizide lowers blood glucose by binding to the SUR1 subunit of ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells, forcing those channels to close, depolarizing the cell membrane, and triggering calcium influx that causes insulin granule exocytosis. Insulin then enters the portal circulation and suppresses hepatic glucose output while promoting peripheral glucose uptake. [6]

This mechanism is strictly glucose-independent. Glipizide stimulates insulin release regardless of the ambient blood glucose concentration. That pharmacological fact explains why hypoglycemia is the drug's most clinically significant adverse effect, particularly if meals are skipped. [7]

The extended-release formulation (Glucotrol XL) uses a patented osmotic pump (GITS technology) to deliver glipizide at a controlled rate over 24 hours, flattening the peak-to-trough insulin secretion curve and modestly reducing hypoglycemia risk compared with the immediate-release tablet. A randomized comparison published in Diabetes Care found that the XL formulation produced equivalent HbA1c lowering with a 15% lower rate of symptomatic hypoglycemia versus immediate-release glipizide given twice daily. [8]

Glipizide also has a mild effect on postprandial glucose excursions when taken 30 minutes before a meal. Timing of the dose relative to food intake is therefore more clinically meaningful for this drug than for most oral antidiabetics. [9]

FDA-Approved Dosing: Immediate-Release and Extended-Release

The FDA-approved starting dose for immediate-release glipizide is 5 mg once daily, taken 30 minutes before breakfast. Patients who are elderly, malnourished, or renally compromised should begin at 2.5 mg. The dose may be titrated upward in 2.5 to 5 mg increments every 1 to 2 weeks based on fasting blood glucose response. Daily doses above 15 mg should be divided into two doses given before meals. The absolute maximum is 40 mg per day. [1]

For the extended-release tablet (Glucotrol XL), the starting dose is 5 mg once daily with breakfast. The maximum approved dose is 20 mg once daily. Patients switching from immediate-release to extended-release use the nearest equivalent total daily dose. [1]

The goal of therapy is typically an HbA1c <7.0% for most non-pregnant adults, per the ADA 2024 standards, though individualized targets between 7.0% and 8.0% are appropriate for patients with limited life expectancy, advanced complications, or high hypoglycemia risk. [3]

Glipizide can be combined with metformin, thiazolidinediones, DPP-4 inhibitors, SGLT-2 inhibitors, or basal insulin. When added to basal insulin, the starting glipizide dose should be reduced by 50% to limit hypoglycemia, per guidance from the American Association of Clinical Endocrinology (AACE). [10]

Glipizide Side Effects: What the Evidence Shows

Hypoglycemia is the dominant safety concern. In a meta-analysis of 38 randomized controlled trials (N=16,986) published in JAMA Internal Medicine, sulfonylureas as a class were associated with a relative risk of 4.57 for symptomatic hypoglycemia compared with placebo. [11] Glipizide's shorter half-life places it toward the safer end of the sulfonylurea class, but hypoglycemia risk is real, especially in older patients and those with irregular meal schedules.

Weight gain is the second most common metabolic consequence. Sulfonylurea-induced insulin secretion promotes fat storage. Clinical trials report average weight gains of 1.5 to 2.5 kg over 6 months of glipizide therapy. [12] This contrasts unfavorably with SGLT-2 inhibitors and GLP-1 receptor agonists, which produce weight loss.

Other documented adverse effects from the FDA prescribing information include:

• Nausea, diarrhea, and epigastric discomfort (2 to 4% of patients)
• Skin reactions including pruritus, erythema, and urticaria (<1%)
• Cholestatic jaundice and hepatic porphyria (rare, <0.1%)
• Hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (case reports)
• Hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [1]

Cardiovascular safety of sulfonylureas has been a subject of ongoing research. The UKPDS 33 trial (N=3,867, 10-year follow-up) found that intensive glucose control with sulfonylureas or insulin reduced any diabetes-related endpoint by 12% versus conventional treatment, with no significant increase in cardiovascular mortality. [13] More recent observational data have raised questions about whether sulfonylureas confer a cardiovascular disadvantage compared with newer agents, but no large dedicated cardiovascular outcomes trial for glipizide specifically has been published.

Drug Interactions That Change Glipizide's Effect

Several drug classes alter glipizide exposure or its hypoglycemic effect, and the FDA label lists these interactions explicitly. [1]

Drugs that potentiate hypoglycemia when combined with glipizide include fluconazole and other azole antifungals (inhibit CYP2C9, raising glipizide levels by up to 56% in pharmacokinetic studies [14]), NSAIDs (displace protein binding), sulfonamide antibiotics, clarithromycin, fibrates, fluoroquinolones, and MAO inhibitors. Beta-blockers mask the tachycardia that signals hypoglycemia.

Drugs that antagonize glipizide and raise blood glucose include thiazide and loop diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, niacin, and sympathomimetics. Patients starting or stopping any of these should have glucose monitoring intensified for 2 to 4 weeks. [1]

Glipizide is metabolized primarily by CYP2C9. Poor metabolizers of CYP2C9 (approximately 3 to 5% of the Caucasian population) may have 2- to 3-fold higher drug exposure, requiring lower doses and more frequent glucose monitoring. [15]

Who Should Not Take Glipizide

Several absolute and relative contraindications apply to glipizide, based on the FDA label and ADA guidelines.

Absolute contraindications include type 1 diabetes mellitus, diabetic ketoacidosis (with or without coma), known hypersensitivity to glipizide or other sulfonylureas, and concurrent use with bosentan (a potent CYP2C9 inducer that dramatically reduces glipizide levels and may cause acute hepatotoxicity through the combination). [1]

Relative contraindications or situations requiring significant dose reduction include:

• Severe hepatic impairment: glipizide is hepatically metabolized, and liver disease prolongs its half-life substantially
• eGFR <30 mL/min/1.73m²: reduced renal clearance of glipizide metabolites extends hypoglycemia risk [16]
• Adrenal or pituitary insufficiency: baseline counter-regulatory hormone deficits amplify hypoglycemia
• Pregnancy: glipizide crosses the placenta; insulin remains the preferred agent for gestational and pregestational diabetes per ACOG guidelines [17]
• Breastfeeding: limited data exist on excretion into breast milk; most guidelines recommend insulin instead [17]

Elderly patients represent a high-risk subgroup. The American Geriatrics Society Beers Criteria lists all sulfonylureas as potentially inappropriate in adults aged 65 and older due to prolonged hypoglycemia risk. [18] When a sulfonylurea is clinically necessary in this population, glipizide at the lowest effective dose is preferred over longer-acting alternatives such as glibenclamide.

Glipizide vs. Metformin: First-Line Positioning

Metformin, not glipizide, is the recommended first-line pharmacological agent for type 2 diabetes in most published guidelines, including those from the ADA, AACE, and the European Association for the Study of Diabetes (EASD). [3] Metformin does not cause hypoglycemia when used as monotherapy, promotes modest weight loss or weight neutrality, has cardiovascular benefit data from the UKPDS 34 subgroup (N=342, overweight patients showed 32% reduction in any diabetes-related endpoint [19]), and costs under $10 per month at most U.S. pharmacies.

Glipizide fills a specific niche: patients who cannot tolerate metformin (primarily due to gastrointestinal side effects or a contraindication such as eGFR <30), patients who need rapid HbA1c reduction before a surgical procedure, and patients for whom GLP-1 agonists and SGLT-2 inhibitors are unaffordable. A 52-week head-to-head trial (N=411) published in Diabetes Care found glipizide and metformin produced equivalent HbA1c reductions of approximately 1.4 percentage points, but patients on glipizide gained 1.7 kg versus a 0.8 kg loss in the metformin group. [20]

Glipizide vs. Newer Agents: GLP-1 Agonists and SGLT-2 Inhibitors

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) have substantially changed the positioning of sulfonylureas in recent years. Both newer classes demonstrate cardiovascular benefit in high-risk T2DM patients, which glipizide does not. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in patients with established cardiovascular disease. [21] The LEADER trial (N=9,340) showed liraglutide reduced the primary MACE endpoint by 13%. [22]

For patients with T2DM and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, the ADA 2024 Standards of Care recommend GLP-1 agonists or SGLT-2 inhibitors as the preferred second agents regardless of HbA1c level. [3] Glipizide is an appropriate choice when these conditions are absent and cost is a limiting factor.

The table below summarizes the key clinical tradeoffs for prescribers choosing between glipizide and the two dominant newer classes.

| Attribute | Glipizide | GLP-1 Agonist | SGLT-2 Inhibitor | |---|---|---|---| | HbA1c reduction | 1.0 to 2.0% | 1.0 to 1.8% | 0.5 to 1.0% | | Weight effect | +1.5 to +2.5 kg | -3 to -6 kg | -2 to -3 kg | | Hypoglycemia risk | Moderate | Low | Low | | CV mortality benefit | Not established | Yes (LEADER, SUSTAIN-6) | Yes (EMPA-REG) | | Monthly cost (generic) | <$10 | $800, $1,200 | $300, $500 | | Route | Oral | Subcutaneous or oral | Oral |

Monitoring Parameters While Taking Glipizide

Patients on glipizide require structured glucose monitoring and periodic laboratory review. Specific targets and intervals recommended by the ADA and AACE are as follows. [3][10]

HbA1c should be checked every 3 months until target is reached, then every 6 months once stable. Fasting plasma glucose targets are typically 80 to 130 mg/dL for most adults and 100 to 180 mg/dL for older or frail patients.

Renal function (serum creatinine, eGFR) should be measured at baseline and at least annually. If eGFR falls below 30 mL/min/1.73m², dose reduction or discontinuation is warranted. [16]

Liver function tests at baseline are advisable given glipizide's hepatic metabolism and rare risk of cholestatic jaundice. Patients who develop jaundice, dark urine, or right-upper-quadrant pain during therapy should have the drug held and liver enzymes checked within 48 hours.

Self-monitoring of blood glucose (SMBG) is particularly important when glipizide is combined with insulin, during illness, before and after strenuous exercise, and whenever a new interacting drug is started or stopped.

Patients should be counseled to carry fast-acting glucose (4 glucose tablets providing 15 to 20 g of carbohydrate) at all times and to follow the "15-15 rule": consume 15 g of glucose, wait 15 minutes, and recheck blood sugar if symptomatic hypoglycemia occurs. If blood glucose remains <70 mg/dL, repeat. [3]

Special Populations: Pregnancy, Renal Disease, and the Elderly

Pregnancy. ACOG and the ADA classify insulin as the first-line pharmacological treatment for both pregestational and gestational diabetes. Glipizide is FDA Pregnancy Category C. It crosses the placental barrier and may cause neonatal hypoglycemia. When oral therapy is clinically required, metformin has more published safety data in pregnancy than glipizide does. [17]

Renal impairment. Because glipizide's primary metabolites are renally excreted, accumulation can occur as eGFR declines. The FDA label recommends starting at 2.5 mg daily in patients with significant renal impairment and titrating cautiously. Most nephrology and diabetes guidelines suggest discontinuing sulfonylureas when eGFR falls <30 mL/min/1.73m² and considering a DPP-4 inhibitor or insulin instead. [16]

Elderly patients. Older adults have slower hepatic metabolism, reduced counter-regulatory hormone responses, and irregular meal patterns, all of which amplify hypoglycemia risk. A prospective cohort study published in JAMA Internal Medicine (N=9,631 patients aged 65 and older) found that sulfonylurea use was associated with a 36% higher rate of serious hypoglycemic events requiring emergency care compared with DPP-4 inhibitor use. [11] If glipizide is used, starting at 2.5 mg and targeting an HbA1c of 7.5 to 8.0% reduces this risk substantially. [18]

Patient Counseling Points: What to Tell Someone Starting Glipizide

The following instructions are drawn directly from the FDA prescribing information and ADA patient education resources. [1][3]

Take immediate-release glipizide 30 minutes before the first meal of the day. The extended-release tablet should be swallowed whole with breakfast. Never crush or chew the XL tablet; doing so destroys the osmotic pump mechanism and delivers the entire dose at once. Do not skip meals after taking the drug. Alcohol increases hypoglycemia risk by impairing hepatic glucose output and should be consumed cautiously.

Symptoms of hypoglycemia include shakiness, sweating, rapid heartbeat, confusion, pallor, and hunger. Blood glucose <70 mg/dL confirms hypoglycemia and requires immediate treatment with fast-acting carbohydrates. Severe hypoglycemia causing loss of consciousness requires glucagon injection (1 mg intramuscular or intranasal) and emergency services.

Glipizide may cause photosensitivity reactions. Patients should use sunscreen and protective clothing during prolonged sun exposure. [1]

Inform your prescriber of all OTC medications, supplements, and herbal products. St. John's Wort, for example, is a CYP2C9 inducer that may reduce glipizide exposure and worsen glycemic control, based on drug interaction modeling data. [15]